EN DE
Watch Venus Remedies Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Venus Remedies Limited (VENUSREM) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Venus Remedies Limited stock ₹1,648, price ₹1,561, upside +5.6%, quality 74 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE411B01019

VR Venus Remedies Limited logo Broad data Nov 14, 2026

Venus Remedies Limited

VENUSREM · NSE

Solid company and rising price, but the stock is already about fairly priced: meets 2 of 3 rules.

Get notified free when this changes
Quality 74/100 
Rising price (uptrend) 
Healthy Growth (revenue 5y +7.0 %/yr in INR) 
Solidly profitable · 14.3% net margin (TTM) 
Low debt 
Generates free cash flow 
Ranks above peers (11/14) 
Broad data 
Last quarter vs. a year ago: revenue +36%, profit +139%. 
Fair value ₹1,648 · Fairly valued 
Moderate moat 63/100
Quality growth
Watch Venus Remedies Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,947 ₹147.75 Fair Value ₹1,648 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range ₹147.75 – ₹1,947 · fair‑value band ₹1,092 – ₹2,229 · the ₹1,561 price screens below the ₹1,648 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 14, 2026.

Follow Venus Remedies in your weekly email

Every Wednesday you see whether Venus Remedies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology.

Show moreShow less

The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine.

The company was incorporated in 1989 and is headquartered in Panchkula, India.

Stock analysis

Venus Remedies Limited (VENUSREM) currently trades at ₹1,561, while our model-based Fair Value estimate is ₹1,648, so the stock looks roughly fairly valued today (gap 5.3%).

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹1,432 per share, and 3 of the 24 models we run sit above the ₹1,561 price.

Bear case: the Economic Profit group reads lowest at ₹508.43, and 21 of the 24 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹1,092 (bear) to ₹2,229 (bull), the price of ₹1,561 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Venus Remedies Limited reported revenue of ₹7.7B in FY2026 versus ₹6.0B in FY2022, a compound +6.5%/yr. Reported net income was ₹1.0B in FY2026, compounding +26.0%/yr from FY2022.

Key figures

Market cap ₹20.9B (≈ $221M) Micro · P/E ratio 17.8 · P/S ratio 2.57 · EPS (TTM) ₹87.46 · Net margin 14.3% · Return on equity 16.8% · Return on assets (EBIT) 6.9% (5-year average) · Operating margin 15.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 63 out of 100 (medium confidence).

What moves the price

The share trades about 20% below its 52-week high and 181% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 6%, VENUSREM screens cheaper than that median.

Fair Value models

Bear ₹1,092 Fair Value ₹1,648 Bull ₹2,229
Price ₹1,561 · Upside +5.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹55.11 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹722.75 ₹1,013 ₹1,379 81
Growth DCF ₹716.94 ₹977.28 ₹1,286 79
Owner Earnings ₹773.34 ₹1,085 ₹1,477 77
All 24 models by family
DCF Models
FCF DCF ₹722.75 ₹1,013 ₹1,379 81
Owner Earnings ₹773.34 ₹1,085 ₹1,477 77
5Y Revenue Exit ₹768.53 ₹1,210 ₹1,780 72
5Y EBITDA Exit ₹898.39 ₹1,461 ₹2,130 74
5Y P/E Exit ₹952.19 ₹1,565 ₹2,226 70
10Y Revenue Exit ₹718.25 ₹1,068 ₹1,550 66
10Y EBITDA Exit ₹803.11 ₹1,211 ₹1,772 68
10Y P/E Exit ₹831.17 ₹1,271 ₹1,833 63
Earnings-Based
Graham-Dodd ₹522.86 ₹1,914 ₹2,584 64
Lynch FV ₹456.42 ₹652.03 ₹847.65 61
PEG = 1.0 ₹456.42 ₹652.03 ₹847.65 57
EPV ₹462.70 ₹510.33 ₹548.27 74
Multiples
P/E Multiple ₹1,269 ₹1,692 ₹2,115 63
P/S Multiple ₹980.36 ₹1,307 ₹1,634 58
P/B Multiple ₹220.84 ₹294.46 ₹368.07 55
EV/EBIT ₹1,174 ₹1,560 ₹1,947 66
EV/EBITDA ₹1,171 ₹1,556 ₹1,942 67
EV/Revenue ₹841.51 ₹1,196 ₹1,551 53
Asset-Based
NCAV (Graham) ₹101.34 ₹153.55 ₹191.94 54
Growth DCF
Growth DCF ₹716.94 ₹977.28 ₹1,286 79
Rev-Margin DCF ₹768.53 ₹1,210 ₹1,741 72
Economic Profit
Residual Income ₹437.78 ₹499.72 ₹652.45 71
ROIC Compounder ₹462.70 ₹517.13 ₹588.40 72
Growth Earnings
Growth-Adj P/E ₹882.60 ₹1,261 ₹1,639 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 74/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 63
How much profit the company makes from its sales and capital
Quality Growth 85
Are margins and returns getting better?
Cashflow 70
Do the profits arrive as real cash?
Financial strength 82
Debt, balance sheet and risk of trouble
Investment 52
Does it invest with discipline instead of growing at any price?
Low Volatility 56
How calm the share price moves, does not count
Price momentum 79
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 86
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 84/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+18.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
Start year 2021 (pandemic). Over 10 years: +6.4% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 13.8% / 32.8%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 16%
2026 sits 261% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2021 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +10.6% a year for the price.

Watch VENUSREM, get fair value alerts →

Compare Venus Remedies Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 74 · Top 25%
Fair Value upside +5.6% · Above median
Profitability
Return on equity (12 months) 16.8% · Top 25%
Return on assets 12.0% · Top 25%
Net margin (12 months) 14.3% · Top 25%
Operating margin (12 months) 15.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 35.6% · Top 25%
Dividend yield (12 months) 0.0% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 17.8× · Cheaper than median
P/B 3.14× · Pricier than median
P/S (12 months) 2.57× · Pricier than median
Price / free cash flow (fiscal year) 17.4× · Cheaper than median
EV/EBITDA 12.3× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)41 · sector 19
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)67 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs VENUSREM
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs VENUSREM
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs VENUSREM
Haleon plc HLN $9.17 $8.47 −8% vs VENUSREM
Merck KGaA MRK €149.70 €108.83 −27% vs VENUSREM
Galderma Group GALD CHF 191.00 CHF 112.30 −41% vs VENUSREM
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs VENUSREM
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs VENUSREM
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs VENUSREM
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs VENUSREM

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Venus Remedies Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Venus Remedies Limited Fair Value". https://www.fairvalue-calculator.com/stock/VENUSREM

Frequently asked questions

Is Venus Remedies Limited (VENUSREM) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ₹1,648 versus a price of ₹1,561, about +6% upside (fairly valued).
What is the fair value of VENUSREM?
Our model-based fair value for Venus Remedies Limited is ₹1,648 (as of Nov 14, 2026), built from audited fundamentals. The current price: ₹1,561.
What is the quality score of VENUSREM?
Venus Remedies Limited has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Venus Remedies Limited (VENUSREM)?
Our model-based price target is the fair value of ₹1,648 (as of Nov 14, 2026) from 24 valuation models. Cautious scenario ₹1,092, optimistic scenario ₹2,229. It is a calculation from audited fundamentals, not an analyst target.
What is the Venus Remedies Limited stock forecast for 2026?
Our models put fair value at ₹1,648, about +6% upside versus a price of ₹1,561 (fairly valued). Cautious scenario ₹1,092, optimistic scenario ₹2,229. The calculation is refreshed regularly with new filings.
What is the revenue of Venus Remedies Limited (VENUSREM)?
Venus Remedies Limited reported trailing-twelve-month revenue of about ₹8.1B (latest available figure, as of Nov 14, 2026).
What growth is priced into Venus Remedies Limited (VENUSREM)?
For today's price to be fair in a discounted-cash-flow model, Venus Remedies Limited would have to grow free cash flow by 15.1 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 7.0 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of VENUSREM use?
Our models discount Venus Remedies Limited at 13.9 %: a base by market capitalisation (micro), damped by beta 0.33, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Venus Remedies Limited that is +15.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has Venus Remedies Limited (VENUSREM) delivered so far?
Over the past 5 years revenue at Venus Remedies Limited grew 7.0 % a year. The price currently implies free-cash-flow growth of +15.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Venus Remedies Limited (VENUSREM) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Venus Remedies Limited (+15.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Venus Remedies Limited (VENUSREM)?
The free-cash-flow yield on the price is 5.73 %: that much free cash flow Venus Remedies Limited produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Venus Remedies Limited (VENUSREM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Venus Remedies Limited it is ₹1,648 per share (as of Nov 14, 2026), against a price of ₹1,561. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Venus Remedies Limited stock overvalued or undervalued in 2026?
As of Nov 14, 2026, VENUSREM trades below its calculated fair value: price ₹1,561, fair value ₹1,648, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VENUSREM?
No. The price is what the market pays today (₹1,561); the fair value is what the company's own numbers justify (₹1,648). For Venus Remedies Limited the two are ₹86.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is Venus Remedies Limited worth?
The market values Venus Remedies Limited at about ₹20.9B (market capitalisation, as of Nov 14, 2026). Per share that is ₹1,561; our models calculate a fair value of ₹1,648 per share.
What do the bullish and bearish scenarios say about VENUSREM?
Our models span a range for Venus Remedies Limited: cautious scenario ₹1,092, base ₹1,648, optimistic ₹2,229 per share (as of Nov 14, 2026, price ₹1,561). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VENUSREM?
Venus Remedies Limited trades at a price-to-earnings ratio of 17.8 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,648 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2017 to 2026), reported earnings: 8.9. Other multiples: P/B 3.1, P/S 2.6, EV/EBITDA 12.3.
How solid is the balance sheet of Venus Remedies Limited (VENUSREM)?
Balance-sheet figures for Venus Remedies Limited (as of Nov 14, 2026): return on equity 16.8%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is VENUSREM from its 52-week high?
Venus Remedies Limited trades at ₹1,561, about 20% below its 52-week high of ₹1,947 and 181% above the low of ₹554.80 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,648 is for.
Which stocks are comparable to Venus Remedies Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Venus Remedies Limited stock attractive at the current price?
The data as of Nov 14, 2026: price ₹1,561, calculated fair value ₹1,648 (+6%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VENUSREM calculated?
We run Venus Remedies Limited through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹1,648 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Venus Remedies Limited currently trades 5% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Venus Remedies Limited (VENUSREM)?
The closing price on Nov 16, 2026 was ₹1,561. Our model-based fair value is ₹1,648, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Venus Remedies Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹1,092 to ₹2,229) leaves room in how you read the outcome.

Key figures of Venus Remedies Limited

How large is the market capitalisation of Venus Remedies Limited (VENUSREM)?
The market capitalisation of Venus Remedies Limited is ₹20.9B (≈ $221M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Venus Remedies Limited (VENUSREM)?
The price-to-sales ratio of Venus Remedies Limited is 2.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Venus Remedies Limited (VENUSREM)?
Earnings per share at Venus Remedies Limited are ₹87.46 (price ÷ EPS = P/E 17.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Venus Remedies Limited (VENUSREM)?
The net margin of Venus Remedies Limited is 14.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Venus Remedies Limited (VENUSREM)?
The return on equity (ROE) of Venus Remedies Limited is 16.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Venus Remedies Limited (VENUSREM)?
On an EBIT basis the return on assets of Venus Remedies Limited is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Venus Remedies Limited (VENUSREM)?
The operating margin of Venus Remedies Limited is 15.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Venus Remedies Limited (VENUSREM)?
Revenue at Venus Remedies Limited is growing 35.6% versus a year earlier (3y avg +11.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Venus Remedies Limited (VENUSREM)?
Earnings per share at Venus Remedies Limited are growing 139% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Venus Remedies Limited (VENUSREM) hold?
Venus Remedies Limited holds more cash than debt, ₹182M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Venus Remedies Limited in the live analysis

One click puts Venus Remedies Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.